Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences (Nasdaq: VTYX) has announced the departure of Martin Auster, M.D. from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the company's SVP of Finance, has been appointed as interim Principal Financial Officer and Principal Accounting Officer for SEC reporting purposes. Ventyx, a clinical-stage biopharmaceutical company focused on developing novel oral therapies for inflammatory diseases, has initiated a search for a new CFO.
CEO Raju Mohan, Ph.D., expressed gratitude for Dr. Auster's contributions over the past three years, including leading the company through its initial public offering, managing financial and governance matters, and supporting investor relations. Dr. Auster reciprocated, stating his pride in the company's accomplishments and wishing Ventyx future success.
Ventyx Biosciences (Nasdaq: VTYX) ha annunciato il congedo di Martin Auster, M.D. dal suo ruolo di Chief Financial Officer, a partire dal 30 agosto 2024. Roy Gonzales, CPA, MBA, il Senior Vice President di Finanza della compagnia, è stato nominato come Principal Financial Officer e Principal Accounting Officer ad interim per le necessità di reporting SEC. Ventyx, un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di nuove terapie orali per le malattie infiammatorie, ha avviato una ricerca per un nuovo CFO.
Il CEO Raju Mohan, Ph.D., ha espresso gratitudine per i contributi del Dr. Auster negli ultimi tre anni, incluso il suo ruolo nella guida dell'azienda durante l'offerta pubblica iniziale, la gestione delle questioni finanziarie e di governance, e il supporto delle relazioni con gli investitori. Il Dr. Auster ha ricambiato, esprimendo il suo orgoglio per i successi dell'azienda e augurando a Ventyx un futuro di successo.
Ventyx Biosciences (Nasdaq: VTYX) ha anunciado la salida de Martin Auster, M.D. de su cargo como Director Financiero, efectivo el 30 de agosto de 2024. Roy Gonzales, CPA, MBA, el Vicepresidente Senior de Finanzas de la compañía, ha sido nombrado como Director Financiero Principal y Director de Contabilidad Principal interino para fines de informes ante la SEC. Ventyx, una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de nuevas terapias orales para enfermedades inflamatorias, ha iniciado la búsqueda de un nuevo CFO.
El CEO Raju Mohan, Ph.D., expresó su gratitud por las contribuciones del Dr. Auster durante los últimos tres años, incluyendo su liderazgo durante la oferta pública inicial de la empresa, la gestión de asuntos financieros y de gobernanza, y el apoyo a las relaciones con los inversores. El Dr. Auster correspondió, expresando su orgullo por los logros de la compañía y deseando a Ventyx un futuro exitoso.
벤티X 바이오사이언스(Nasdaq: VTYX)는 마틴 아우스터, M.D.가 최고 재무 책임자 직에서 물러난다고 발표했습니다. 이는 2024년 8월 30일자로 효력이 발생합니다. 회사의 재무 부사장인 로이 곤살레스(CPA, MBA)가 SEC 보고를 위한 임시 재무 책임자 및 회계 책임자로 임명되었습니다. 벤티X는 염증성 질환을 위한 새로운 경구 치료제 개발에 중점을 둔 임상 단계의 바이오 제약 회사로, 새로운 CFO를 찾기 위한 절차를 시작했습니다.
CEO 라주 모한(Ph.D.)은 지난 3년간 드 아우스터 박사의 기여에 감사를 표하며, 회사의 최초 공개와 재무 및 거버넌스 문제 관리, 투자자 관계 지원 등을 언급했습니다. 드 아우스터 박사도 회사를 자랑스럽게 여긴다며 벤티X의 미래 성공을 기원했습니다.
Ventyx Biosciences (Nasdaq: VTYX) a annoncé le départ de Martin Auster, M.D. de son poste de directeur financier, à compter du 30 août 2024. Roy Gonzales, CPA, MBA, le vice-président senior des finances de l'entreprise, a été nommé directeur financier et directeur comptable principal par intérim à des fins de déclaration auprès de la SEC. Ventyx, une société biopharmaceutique en phase clinique axée sur le développement de nouvelles thérapies orales pour les maladies inflammatoires, a lancé une recherche pour un nouveau directeur financier.
Le PDG Raju Mohan, Ph.D., a exprimé sa gratitude pour les contributions du Dr Auster au cours des trois dernières années, y compris son rôle dans la direction de l'entreprise lors de son introduction en bourse, la gestion des affaires financières et de gouvernance, et le soutien aux relations avec les investisseurs. Le Dr Auster a également exprimé sa fierté pour les réalisations de l'entreprise et a souhaité un avenir prospère à Ventyx.
Ventyx Biosciences (Nasdaq: VTYX) hat den Rücktritt von Martin Auster, M.D. als Chief Financial Officer bekannt gegeben, der am 30. August 2024 wirksam wird. Roy Gonzales, CPA, MBA, der Senior Vice President für Finanzen des Unternehmens, wurde zum interimistischen Principal Financial Officer und Principal Accounting Officer für SEC-Berichtszwecke ernannt. Ventyx, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger oraler Therapien für entzündliche Krankheiten konzentriert, hat die Suche nach einem neuen CFO eingeleitet.
CEO Raju Mohan, Ph.D., drückte seine Dankbarkeit für die Beiträge von Dr. Auster in den letzten drei Jahren aus, darunter die Führung des Unternehmens durch den Börsengang, das Management von finanziellen und Governance-Angelegenheiten sowie die Unterstützung der Investorenbeziehungen. Dr. Auster erwiderte, dass er stolz auf die Erfolge des Unternehmens sei und Wünschen Ventyx viel Erfolg in der Zukunft.
- Smooth transition with interim financial leadership in place
- Company has initiated a search for a new CFO
- Departure of Chief Financial Officer
- Potential disruption in financial leadership during transition period
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company’s SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
“Marty has been a valued member of our executive team over these past three years,” said Raju Mohan, Ph.D., Chief Executive Officer. “I want to thank Marty for his contributions to Ventyx’s success, including leading the Company through its initial public offering, managing financial and governance matters, and supporting investor relations. We wish him well in his future endeavors.”
“It has been a privilege to work as part of Ventyx’s leadership team and I am proud of our accomplishments,” said Dr. Auster. “I wish the Company great success in the future.”
About Ventyx Biosciences
Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with inflammatory diseases. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift inflammation markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
FAQ
Who is departing as CFO of Ventyx Biosciences (VTYX)?
Who will assume the interim financial leadership roles at Ventyx Biosciences (VTYX)?
What is Ventyx Biosciences (VTYX) focused on as a company?
What were Martin Auster's key contributions to Ventyx Biosciences (VTYX)?
